SCHEMBL5060253

SCHEMBL5060253

O=C(O)C(c1cccnc1)C(F)P(=O)(O)Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 1/20 0.46
GRM4 Q14833 1/20 0.46
ANPEP P15144 1/20 0.42
ERAP2 Q6P179 1/20 0.42
ERAP1 Q9NZ08 1/20 0.42
FDPS P14324 5/20 0.42
KCNN4 O15554 2/20 0.42
KCNA5 P22460 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41
EPHX2 P34913 1/20 0.40
TBXAS1 P24557 1/20 0.40
SLC1A2 P43004 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NAPRT Q6XQN6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5060077 0.86 CYP2D6 (0.42) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL5060437 0.78 TBXAS1 (0.44) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL7604050 0.74 GRM8 (0.45) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL5053344 0.74 FDPS (0.50) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL7606691 0.73 GPR132 (0.47) GRM8GRM4FDPSKCNN4KCNA5
SCHEMBL7605062 0.73 GRM8 (0.44) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL5053039 0.73 TBXAS1 (0.55) GRM8GRM4EPHX2TBXAS1
SCHEMBL5051271 0.73 GRM8 (0.42) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL5134132 0.73 ANPEP (0.44) GRM8GRM4ANPEPERAP2ERAP1
SCHEMBL8843555 0.73 GRM8 (0.48) GRM8GRM4FDPSKCNN4KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0994707-A4 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2001-11-14 EP claimed
EP-0994707-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 2000-04-26 EP claimed
WO-1998053812-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1998-12-03 WO claimed
US-20080311037-A1 Compounds which bind PSMA and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 US disclosed
WO-2006093991-A1 COMPOUNDS WHICH BIND PSMA AND USES THEREOF THE CLEVELAND CLINIC FOUNDATION (US) 2006-09-08 WO disclosed
EP-0994707-A4 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2001-11-14 EP disclosed
EP-0994707-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 2000-04-26 EP disclosed
US-6025345-A NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, GUILFORD PHARMACEUTICALS INC. (US) 2000-02-15 US disclosed
WO-1998053812-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311037-A1 Compounds which bind PSMA and uses thereof FOLH1, PSMA1, BPHL GRM8 2890/4885GRM4 3118/4885ANPEP 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.